News

August 1, 2019

EIP Pharma to Present at Canaccord Genuity 39th Annual Growth Conference

EIP Pharma, Inc., a CNS-focused therapeutics company, today announced that company management will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019, at 12:00 p.m. ET in Boston, MA.

Read More

July 17, 2019

EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38α Kinase Inhibitor Neflamapimod on the Neurodegenerative Process

Presentations at Late Breaker Session at Alzheimer’s Association International Conference (AAIC) 2019 Cambridge, Mass., July 17, 2019 – EIP Pharma, Inc., a CNS-focused therapeutics company, today announced that new preclinical data regarding neflamapimod were presented at the AAIC 2019 scientific meeting in Los Angeles, CA (July 14-18, 2019). “The findings add to the growing body […]

Read More

July 12, 2019

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies

The primary objective of the study is to determine whether neflamapimod, a brain-penetrant, oral small molecule that inhibits the enzyme p38 alpha, can reverse the hippocampal synaptic dysfunction associated with DLB. 

Read More

View All News



Presentations




View All Presentations

About EIP

Are you a patient, caregiver, clinician or professional and want to learn more about EIP Pharma’s approach? Please contact us.

Contact Us